Alendronate plus cholecalciferol for the treatment of osteoporosis

Robert P. Heaney

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Osteoporosis is a common medical condition in older individuals, responsible for approximately 1.5 million fragility fractures in the USA each year. Alendronate sodium with cholecalciferol (vitamin D3) is a newly developed combination formulation for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis. It complements the existing once-weekly dosage formulation of alendronate sodium alone, providing, in addition to alendronate, a 2800 international unit (IU) dose of cholecalciferol (vitamin D3), equivalent to 400 IU daily. Its efficacy in reducing fracture risk is expected to be at least as good as that of once-weekly alendronate given for the same indications.

Original languageEnglish
Pages (from-to)23-27
Number of pages5
JournalWomen's Health
Volume2
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Alendronate
Cholecalciferol
Osteoporosis
Therapeutics
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Alendronate plus cholecalciferol for the treatment of osteoporosis. / Heaney, Robert P.

In: Women's Health, Vol. 2, No. 1, 01.2006, p. 23-27.

Research output: Contribution to journalArticle

Heaney, Robert P. / Alendronate plus cholecalciferol for the treatment of osteoporosis. In: Women's Health. 2006 ; Vol. 2, No. 1. pp. 23-27.
@article{9c155b6b80ae49349d95642a6c888c32,
title = "Alendronate plus cholecalciferol for the treatment of osteoporosis",
abstract = "Osteoporosis is a common medical condition in older individuals, responsible for approximately 1.5 million fragility fractures in the USA each year. Alendronate sodium with cholecalciferol (vitamin D3) is a newly developed combination formulation for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis. It complements the existing once-weekly dosage formulation of alendronate sodium alone, providing, in addition to alendronate, a 2800 international unit (IU) dose of cholecalciferol (vitamin D3), equivalent to 400 IU daily. Its efficacy in reducing fracture risk is expected to be at least as good as that of once-weekly alendronate given for the same indications.",
author = "Heaney, {Robert P.}",
year = "2006",
month = "1",
doi = "10.2217/17455057.2.1.23",
language = "English",
volume = "2",
pages = "23--27",
journal = "Women's health (London, England)",
issn = "1745-5065",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Alendronate plus cholecalciferol for the treatment of osteoporosis

AU - Heaney, Robert P.

PY - 2006/1

Y1 - 2006/1

N2 - Osteoporosis is a common medical condition in older individuals, responsible for approximately 1.5 million fragility fractures in the USA each year. Alendronate sodium with cholecalciferol (vitamin D3) is a newly developed combination formulation for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis. It complements the existing once-weekly dosage formulation of alendronate sodium alone, providing, in addition to alendronate, a 2800 international unit (IU) dose of cholecalciferol (vitamin D3), equivalent to 400 IU daily. Its efficacy in reducing fracture risk is expected to be at least as good as that of once-weekly alendronate given for the same indications.

AB - Osteoporosis is a common medical condition in older individuals, responsible for approximately 1.5 million fragility fractures in the USA each year. Alendronate sodium with cholecalciferol (vitamin D3) is a newly developed combination formulation for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis. It complements the existing once-weekly dosage formulation of alendronate sodium alone, providing, in addition to alendronate, a 2800 international unit (IU) dose of cholecalciferol (vitamin D3), equivalent to 400 IU daily. Its efficacy in reducing fracture risk is expected to be at least as good as that of once-weekly alendronate given for the same indications.

UR - http://www.scopus.com/inward/record.url?scp=33646787856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646787856&partnerID=8YFLogxK

U2 - 10.2217/17455057.2.1.23

DO - 10.2217/17455057.2.1.23

M3 - Article

VL - 2

SP - 23

EP - 27

JO - Women's health (London, England)

JF - Women's health (London, England)

SN - 1745-5065

IS - 1

ER -